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Abstract
A Virtual Patient (VP) is a computational model accounting for individualised
(patho-) physiology and Pharmaco-Kinetics/Dynamics of relevant drugs. Avail-
ability of VPs is among the enabling technology for In Silico Clinical Trials. Here
we shortly outline the state of the art as for VP generation and summarise our
recent work on Artificial Intelligence (AI) and Statistical Model Checking based
generation of VPs.
1 Introduction
Assessing safety and efficacy of pharmaceutical drugs and treatments is typically done through Randomised
In Vivo Clinical Trials (RVCTs) which tests the candidate drug/treatment on suitably chosen patients.
Unfortunately this approach has many drawbacks. First, it is very time consuming: in many cases, even
more than 5 years are needed to have a new drug approved by the regulatory bodies. Second, it is very
expensive: hundreds of million Euros are typically spent to complete a RVCT. Third, it is hardly usable
for rare diseases, because of costs and lack of patients.
The above state of affairs motivates investigation of methods that can save on time and costs for safety
and efficacy assessment of drugs and treatments. In such a scenario, the In Silico Clinical Trials (ISCTs)
approach is one of the most promising ones. Shortly, much as done in simulation-based verification
of Cyber-Physical Systems (CPSs), ISCTs replace the physical system (a patient in this case) with
a computational model, a Virtual Patient (VP), accounting for the relevant features of the physical
system. Basically, a VP is a computational model encompassing patient (patho-) physiology along with
Pharmaco-Kinetics/Dynamics (PKPD) of relevant drugs. In such a context, safety and efficacy assessment
can be done by simulating the effect of the drug on, ideally, all VPs, exactly as, ideally, CPS verification
aims at evaluating requirements under all possible operational scenarios.
2 State of the art
ISCTs basically entail the following steps. First, generate a set of VPs whose predictions are in agreement
with (patho-) physiology, PKPD, and in vivo clinical data. This model validation activity is done once
and for all. Second, use the above in vivo validated VPs to assess, through simulation, safety and efficacy
of a candidate drug.
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The main obstacle to overcome to carry out an ISCT is the generation of a cohort of VPs that is
complete, i.e., is large enough to represent all relevant human patient phenotypes, and is minimal, i.e.,
does not contain behaviours that are not compatible with the human (patho-) physiology of interest. In
the following we briefly review the state of the art on VPs generation methods.
First, we note that achieving simultaneously completeness and minimality is presently out of reach.
Thus, usually, completeness is privileged. Basically, this aims at guaranteeing that all human patient
phenotypes are adequately represented in silico.
Computational models for VPs are usually developed using medical knowledge from the literature and
from pathway databases such as KEGG (Kyoto Encyclopedia of Genes and Genomes) or Reactome. Open
formats, such as the Systems Biology Markup Language (SBML), allow exchange of computational models
across platforms and their integration within open-standard general-purpose simulation ecosystems [27].
Unfortunately, physiology knowledge is often qualitative. To overcome such an obstacle, many
qualitative as well as quantitative approaches have been devised. An overview is in [45].
Qualitative approaches, often referred to as logic based, discretise the values of interest. In this context,
Boolean models have been widely studied (see, e.g., [18] and citations thereof). Logical models are very
useful for a qualitative analysis, but are quite difficult to use within a compositional framework where
quantitative models from physiology or pharmacology are present. Since in an ISCT quantitative aspects
are extremely relevant (e.g., drug dosage) we will focus on quantitative models.
Quantitative models typically focus on representing dynamics of chemical reactions through Ordinary
Differential Equations (ODEs) with stoichiometric parameters and reaction rates estimated from clinical
data using model identification techniques, as, e.g., in [56]. Such models are typically used to support
ISCT, as, e.g., in [26]. The main obstacle to overcome in using quantitative models is the lack of knowledge
about the values for their parameters. In fact, very few model parameter values can be estimated using
clinical data (see, e.g., [52] for a survey). As a result, most parameter values have to be estimated through
computational methods, typically using model identification techniques (see, e.g., [58, 55]).
In such a setting two approaches are typically used: those based on optimisation techniques and those
based on statistical techniques.
Both global and local optimisation-based approaches, relying on Artificial Intelligence (AI) as well as on
numerical methods, have been widely studied. Global optimisation–based approaches are computationally
heavy, however convergence is guaranteed to a global optimum (see, e.g., [28, 57, 43]). On the other hand,
local optimisation approaches (e.g., [29, 35, 39]) are in general computationally lighter than global ones,
but convergence is only guaranteed towards a local optimum (e.g., [20, 21, 41]). The reader is referred to,
e.g., [44] for an in-depth comparison among the two approaches and [31] for an example of use of AI-based
optimisation techniques for computing personalised treatments.
Typically, both global as well as local optimisation approaches rely on model identifiability, i.e.,
different values for the model parameters lead to different model behaviours (see, e.g., [25]). In such a
case, different model identification techniques can be used. Examples are in [9, 46, 10, 54, 1, 50].
When clinical data are scarce, identification approaches can be applied by averaging data coming from
different patients. However, the resulting parameter value yields an inter-patient model behaviour (see,
e.g., [47]).
Since the goal of the above mentioned approaches is to generate a model parameter value that fits
available experimental data, a huge amount of data per patient is needed in order to generate a virtual
population that is representative of all human phenotypes. As a result, generating a complete set of
VPs using model identification techniques would require considering a large amount of patients (ideally
at least one for each relevant phenotype) along with a huge amount of clinical data for each of such
patients. Unfortunately, this is exactly one of the obstacles ISCTs aims at overcoming. Thus, while model
identification techniques are essential to validate models against clinical data and to develop patient-specific
models, they can be hardly used to generate a complete set of VPs.
Moreover, VP models are often globally or partially unidentifiable, i.e., wide ranges of parameter
values lead to very similar model behaviours (see, e.g., [8]). However, being able to generate VPs (i.e.,
parameter values) which yield clearly distinguishable model behaviours is of crucial importance for ISCTs.
Statistical approaches are also widely used. In such approaches a parameter probability distribution,
rather than a single value, is inferred (see, e.g., [17, 22, 49]). They are typically used for physiology-based
PKPD models (see, e.g., [48]), i.e., quantitative VP models where parameter values are measurable
physiological quantities (such as blood flow, organ volumes, etc). Unfortunately, most VP models have
In Silico Clinical Trials through AI and Statistical Model Checking 3
p
g/
m
L
days
(a)
n
g/
m
L
days
(b)
IU
/L
days
(c)
IU
/L
days
(d)
 0
 50
 100
 150
 200
 250
 300
 350
 400
 450
 0  5  10  15  20  25  30
Species #24 - E2: estradiol
patient-specific prediction
default
log
p
g/
m
L
days
(e)
 2
 3
 4
 5
 6
 7
 8
 9
 10
 11
 12
 0  5  10  15  20  25  30
Species #7 - FSH_blood: FSH in the blood
patient-specific prediction
default
log
IU
/L
days
(f)
Figure 1: (a)–(d): system trajectories under all Biologically Admissible (BA) parameters (dark blue
curves denote trajectories under default parameter); (e)–(f): patient-specific (green curves) vs. default
predictions (blue curves) for, respectively, E2 and FSH.
hard-to-measure parameters such as stoichiometric constants and reaction rates. In fact, probability
distribution functions for them are typically unknown.
Limited knowledge about VP model parameters calls for methods that handle models whose parameters
are partially unknown. This guarantees completeness, possibly at the price of minimality. In other words,
we use an over-approximation of the set of all physiologically admissible (i.e., whose behaviour is plausible
with respect to physiology) VPs.
Since model-checking techniques enable exploration of all possible behaviours of a model, it is not
surprising that such approaches have been investigated in order to generate VPs for both qualitative as
well as quantitative VP models. In particular, for qualitative models (e.g., Boolean models) the problem
of finding model parameter values yielding a biological meaningful behaviour is reduced to the problem of
finding stable states of the model, i.e., attractors. In such a setting, symbolic model checking is widely
used (see, e.g., [42, 13, 2, 19]). There, physiological admissibility can be defined using a temporal logic,
such as CTL or LTL. Some examples are in [7, 6, 5, 11, 4] or in [15], where a probabilistic model checking
approach is used.
Unfortunately, even using model approximation techniques like those in [3, 40], the above mentioned
model checking approaches cannot be used to generate VPs from quantitative ODE-based models, i.e.,
those sought to support ISCTs. Indeed, in such a setting only simulation-based approaches are viable.
This suggests to investigate use of Statistical Model Checking (SMC) techniques to support VP generation.
3 Generating a complete set of Virtual Patients
Here we outline our AI and SMC based VP generation algorithms described in [53, 38]. Our algorithms
take as input an ODE model for a biological system along with default values for all model parameters.
Such default values are typically obtained by averaging among the behaviour of many patients (inter-patient
model), as, e.g., in [47]. Our approach can be summarised as follows.
Formalisation of biological admissibility In order to build a general-purpose tool that can auto-
matically search through millions of model parameter values we need a criterion to automatically filter
out (most of) the parameter values leading to time evolutions that are not biologically meaningful. We
provide such a criterion by defining, as BA parameter values, those entailing time evolutions having a
second-order statistics close enough to that of the model default parameter values.
Computation of a complete set of Virtual Patients Our goal is to compute a set of BA values
for the model parameters (VPs) that encompasses as many biologically meaningful behaviours as possible,
but at the same time is not too large, in order to speed up our on-line computation. Thus, taking into
account that differences in values below a certain threshold are meaningless from a biological point of
view, we discretise the range of values for each model parameter. In such a framework, we present a SMC
based algorithm that computes a set S containing only and (with arbitrarily high confidence) all BA
values for our model parameters. Note that such an algorithm does not depend on patient-specific data.
Thus it can be run once and for all off-line, and its output can be stored for further processing.
Basically, our algorithm makes an AI-guided sampling of the space of the model parameters (building
on our Model Checking (MC) tools in, e.g., [32, 14, 33, 34, 37, 30]) and then uses hypothesis testing–based
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SMC (as in [12, 36]) to guarantee, with any user-provided statistical confidence, completeness of the set
of VPs generated.
Effectiveness of our approach has been evaluated on GynCycle, a model of the hormones regulating
the human female menstrual cycle introduced in [47]. As hormonal regulatory systems occur within a
complex network of endocrinological, neurological, and psychological factors [16, 24, 23], they are difficult
to capture within clinical studies, and model-based approaches might be of great aid in taking these many
factors under better control. GynCycle has 114 parameters, 75 of which are patient-specific (at least for
our purposes), and consists of 41 algebraic-differential equations defining the time evolution of 33 species.
We experimentally evaluate soundness and completeness of our notion of biological admissibility, using
reference values from the literature (e.g., [51]) and a dataset (courtesy of Pfizer), encompassing daily
measurements of the blood level of E2, P4, FSH, and LH on 12 women during an entire menstrual cycle
(totalling more than 1000 data points). Figures 1a to 1d show the trajectories for those 4 hormones
obtained by running the GynCycle model on all parameter values computed by our algorithm. We see
that most of such trajectories are biologically meaningful, being in agreement with the trajectories in [51].
This shows (experimentally) soundness of our biological admissibility notion. Furthermore (experimental
completeness), most of the measurements in our dataset (red crosses in Figures 1a to 1d) lie within the
region covered by our trajectories.
Figures 1e and 1f give an example of patient-specific (i.e., using our computed model parameters)
predictions for, respectively, E2 and FSH and compare them with default predictions (i.e., using the
default model parameters) and in vivo clinical measurements. The achieved error reduction is of about
10%. This value has a relevant impact from a clinical standpoint, as it can move hormone peaks (which
are among the main fertility/infertility indicators) by several days (see Figures 1a to 1d).
4 Conclusions
Computation of a complete set of VPs is among the enabling technology for ISCTs. We have shown how
using synergies between AI and SMC techniques it is possible to effectively generate a complete set of
VPs starting from an ODE model and default values to the model parameters.
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